Skip Navigation
Skip to contents

Intest Res : Intestinal Research

IMPACT FACTOR

Author index

Page Path
HOME > Browse articles > Author index
Search
Mengqi Chen 1 Article
IBD
Comparative effectiveness of ustekinumab versus infliximab in the management of perianal fistulizing Crohn's disease: a retrospective study in China
Mengqi Chen, Zihan Chen, Jianming Lin, Linxin Liu, Tong Tu, Xiaoling Li, Baili Chen, Yao He, Minhu Chen, Zhirong Zeng, Xiaojun Zhuang
Intest Res 2026;24(1):52-63.   Published online June 11, 2025
DOI: https://doi.org/10.5217/ir.2024.00168
AbstractAbstract PDFPubReaderePub
Background/Aims
Ustekinumab (UST) and infliximab (IFX) are both effective in the treatment of perianal fistulizing Crohn’s disease (CD), but limited research has focused on comparing the efficacy of UST versus IFX in this field. This study aimed to compare the effectiveness of UST or IFX in treating perianal fistula of CD patients naive to biological agents in a real-world setting.
Methods
A retrospective cohort study included patients with perianal fistulizing CD treated with UST or IFX was conducted to evaluate the rates of luminal and perianal fistula response and remission at 6 months after treatment.
Results
Ninety-seven patients (49 UST and 48 IFX) were enrolled. Compared to IFX, UST exhibited significantly higher rates of treatment success (89.8% vs. 50.0%, P< 0.001) and intestinal clinical response (85.7% vs. 68.8%, P= 0.048), but no significant differences in fistula remission, fistula response, fistula closure, intestinal clinical remission, endoscopic remission and endoscopic response was observed. Furthermore, multivariate analyses demonstrated complexity of fistula was conversely associated with fistula remission between the UST and IFX groups. Finally, the rates of disease relapse and operation in the IFX group were higher as compared to the UST group during follow-up.
Conclusions
UST may serve as a promising alternative to IFX for the treatment of perianal fistulizing CD.

Citations

Citations to this article as recorded by  
  • The efficacy of ustekinumab in the management of perianal fistulizing Crohn’s disease
    Hee Seok Moon
    Intestinal Research.2026; 24(1): 1.     CrossRef
  • Advanced Medical Therapies for Perianal Fistulizing Crohn’s Disease: A Systematic Review of Clinical, Radiological, Surgical, and Composite Outcomes
    Fares Jamal, Tayo Segun-Omosehin, Taylor Viggiano, Hamza Khan, Alejandro J. Gonzalez, Geoff Thomas, Sandra Elmasry, Talha A. Malik
    Pharmaceuticals.2026; 19(3): 417.     CrossRef
  • Medical Therapies Beyond Infliximab for Perianal Fistulizing Crohn’s Disease: Current Evidence and Future Perspectives
    Esteban Fuentes-Valenzuela, Francisco Javier Tarrasó, Belén Botella, Pilar Nos, Isabel Vera, Marisa Iborra
    Journal of Clinical Medicine.2026; 15(18): 7327.     CrossRef
  • 8,141 View
  • 421 Download
  • 3 Crossref
Close layer

Intest Res : Intestinal Research
Close layer
TOP